RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres

BACKGROUND: Treatment options for patients with metastatic colorectal cancer (mCRC) include anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS wild-type tumours only and require prior mutation testing of “hot-spot” codons in exons 2, 3 and 4 of KRAS and NRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Boleij, Annemarie, Tack, Véronique, Taylor, Aliki, Kafatos, George, Jenkins-Anderson, Sophie, Tembuyser, Lien, Dequeker, Els, van Krieken, J. Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080758/
https://www.ncbi.nlm.nih.gov/pubmed/27784278
http://dx.doi.org/10.1186/s12885-016-2810-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080758/
https://www.ncbi.nlm.nih.gov/pubmed/27784278
http://dx.doi.org/10.1186/s12885-016-2810-3

Ejemplares similares